1. [Combined liver-kidney and kidney after liver transplantation: indications and experiences from a nephrological perspective at a single center].
- Author
-
Seckinger J, Tönshoff B, Stremmel W, Zeier M, and Schmidt J
- Subjects
- Adolescent, Adult, Calcineurin Inhibitors, Child, Child, Preschool, Combined Modality Therapy, Diabetic Nephropathies mortality, Diabetic Nephropathies surgery, Female, Glomerulonephritis mortality, Glomerulonephritis surgery, Graft Rejection immunology, Graft Rejection prevention & control, Hepatorenal Syndrome, Humans, Hyperoxaluria, Primary mortality, Hyperoxaluria, Primary surgery, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Infant, Kidney Failure, Chronic chemically induced, Kidney Failure, Chronic mortality, Kidney Transplantation immunology, Kidney Transplantation mortality, Liver Cirrhosis mortality, Liver Cirrhosis surgery, Liver Failure mortality, Liver Transplantation immunology, Liver Transplantation mortality, Male, Middle Aged, Polycystic Kidney Diseases mortality, Polycystic Kidney Diseases surgery, Reoperation, Retrospective Studies, Survival Rate, Young Adult, Kidney Failure, Chronic surgery, Kidney Transplantation methods, Liver Failure surgery, Liver Transplantation methods
- Abstract
Combined liver-kidney transplantations (CLKT) and kidney after liver transplantations (KALT) are established treatments for patients with end-stage hepatic and renal disease and the number of transplantations has continuously increased over the past few years. The most frequent indications for CLKT in adults are polycystic kidney disease with severe liver involvement and liver cirrhosis of different origins with concomitant chronic kidney failure due to chronic glomerulonephritis or diabetic nephropathy. In children, CLKT is most frequently required due to primary oxalosis type I. At present the main indication for KALT still is calcineurin inhibitor-induced chronic nephrotoxicity, emphasizing the need for a nephron-sparing long-term immunosuppression in liver transplant recipients. Compared to KALT, the indications for CLKT are not as well defined and the decision must therefore be made on a case-by-case basis by a multidisciplinary team of experienced clinicians to avoid unnecessary transplantations of both organs in patients with reversible kidney failure, given the scarcity of organs for transplantation worldwide. In hepatorenal syndrome CLKT should only be considered if the GFR is lower than 20 ml/min for more than three months or if the patient has been on renal replacement treatment for more than one month. In CLKT, there appears to be a certain immunological protection for the kidney transplant by the liver transplant., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2010
- Full Text
- View/download PDF